Tillotts Pharma in-licenses IBD candidate from Numab

Switzerland-based Tillotts Pharma AG, part of Japan’s Zeria Group (TYO: 4559), and privately-held Numab AG have entered into an exclusive global licensing agreement to develop and commercialize new antibody-based therapies that act against tumor necrosis factor alpha (TNF-α) for people with inflammatory bowel disease (IBD).

The partnership demonstrates Tillotts’ commitment to developing new treatments to improve care for patients with IBD and, upon successful development, will add to a strong track record in the registration and marketing of IBD treatments globally.

Anti-TNF therapy has been shown to reduce hospitalizations and surgeries, and improve quality of life. Under the terms of the agreement, Tillotts will develop and commercialize new formulations of anti-TNF-antibody fragments identified by Numab.

Terms of the collaboration; co-development partner will be saught